Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study

BACKGROUND: Apatinib, a small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor-2, has clinical activity in recurrent/advanced gynecological cancers. However, its efficacy in uterine malignancy remains unclear. This study aimed to determine the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Yulan, Wang, Tingting, Cheng, Xi, Ke, Guihao, Huang, Yan, Yang, Huijuan, Huang, Xiao, Tian, Wenjuan, Wang, Huaying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929780/
https://www.ncbi.nlm.nih.gov/pubmed/36819505
http://dx.doi.org/10.21037/atm-22-6463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929780/
https://www.ncbi.nlm.nih.gov/pubmed/36819505
http://dx.doi.org/10.21037/atm-22-6463

Ejemplares similares